LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
23.2.2021 01:33:00 EET | Business Wire | Press release
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
Contact information
Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 15:30:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the checkout flow and assert the console has no errors." "Log in and store the session cookie value." "Assert localStorage contains the selected product ID." "Open th
Allegro DVT’s Pulsar Decoder IP Adds Support for AV2 Video Codec16.6.2026 15:30:00 EEST | Press release
Allegro DVT, the leader in Semiconductor Video IPs and Video Compliance Tools, announces the availability its real-time AV2 Decoder IP integrated into its Pulsar™ D400 Series Multi-Standard Decoding IP. This milestone is a follow-up to the company’s announcement in September 2026 that underscored its plans to develop solutions for the emerging AV2 ecosystem spanning both video compliance tools and semiconductor IPs. As global demand for high-quality streaming continues to accelerate, AV2 is emerging as the next major open, royalty-free video compression standard. Developed by the Alliance for Open Media (AOM), AV2 represents a generational leap in video coding, designed to address evolving streaming requirements and enable new media experiences. Building on the success of AV1, AV2 introduces capabilities that support advanced applications such as immersive content (AR/VR), multi-view and split-screen streaming, and improved screen content handling, while operating across a wider range
Sai Life Sciences Achieves EcoVadis Platinum Rating, Joining the Top 1% of Companies Assessed Worldwide16.6.2026 15:27:00 EEST | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs) has secured the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies assessed worldwide for sustainability performance. With an overall score of 87/100 and a 99th percentile ranking, Sai Life Sciences has achieved Platinum Medal in ‘Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations’ category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616260047/en/ Sai Life Sciences achieves EcoVadis Platinum Rating, joining the top 1% of companies assessed worldwide Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sustainability is becoming one of the defining measures of excellence in our industry. The ability to innovate, grow and create impact must be matched by an equal commitment
Plaud Scales From $1M to $100M ARR Within Two Years, Bringing AI Beyond the Screen for Professionals16.6.2026 15:25:00 EEST | Press release
Plaud, the company building real-world AI interface for professionals, today announced it has scaled from $1M to $100M in ARR within two years, placing it among the fastest AI companies globally to reach the milestone. Plaud is the only hardware-enabled AI company in a cohort otherwise dominated by software-only players, and now serves more than 2 million professionals across 170+ countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616945160/en/ The fastest AI growth stories have, until now, belonged almost entirely to software-native companies: AI coding tools, enterprise workflow agents, and other SaaS products scaling behind screens and keyboards. Plaud's growth represents a different model — recurring AI software scaled through a real-world physical interface, with devices (Plaud Note, Plaud Note Pro, Plaud NotePin S) acting as the entry point into human conversations, capturing the upstream, lossless, source-of
Rehlko Integrates WB Power Services into its UK and EMEA Platform, Expanding Lifecycle Capabilities for Mission-Critical Power16.6.2026 15:00:00 EEST | Press release
Rehlko, a global energy resilience leader delivering innovative solutions across industrial energy systems, powertrain technologies, and home energy applications, today announced that its UK business, formerly WB Power Services, has been fully brought onto the Rehlko platform, strengthening the company’s UK and Europe, Middle East, and Africa (EMEA) operating model and expanding its ability to deliver end-to-end lifecycle solutions for mission-critical power applications. The move aligns the former WB Power Services’ long-established UK capabilities – including engineering, installation, commissioning, and long-term service – with Rehlko’s broader platform. It represents an important step in scaling consistent, high-quality delivery across priority markets as demand accelerates in data centers and other mission-critical environments. Customers increasingly require partners that can deliver reliable, repeatable solutions across the full project lifecycle and over long operating horizons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom